Straits Times Index
3,320.57 -5.71 (-0.17%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,066.02 -6.88 (-0.04%) FTSE 100
8,272.84 +25.05 (+0.30%) Bitcoin USD
61,712.18 +820.27 (+1.35%) CMC Crypto 200
1,277.61 -6.17 (-0.48%)
Evoke Pharma Inc (EV00.BE)
| Previous close | 0.5350 |
| Open | 0.4660 |
| Bid | 0.4620 x N/A |
| Ask | 0.5500 x N/A |
| Day's range | 0.4660 - 0.4660 |
| 52-week range | 0.3780 - 1.5900 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth st
- GlobeNewswire
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
Evoke commercial booth located at site #737SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 20
- GlobeNewswire
Evoke Pharma Reports First Quarter 2024 Financial Results
114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March
